<DOC>
	<DOCNO>NCT01600950</DOCNO>
	<brief_summary>The study involve single injection LY2963016 single injection Lantus , 2 separate occasion participant type I diabetes . Following dose , participant undergo glucose clamp last 42 hour time . There least 7 day two period , time study treatment , participant resume regular therapy . The duration study 9.5 week . The purpose study understand blood sugar lower effect LY2963016 compare Lantus , determine LY2963016 Lantus metabolize participant type I diabetes .</brief_summary>
	<brief_title>A Study Compare LY2963016 Lantus After Single Dose Participants With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 1 diabetes mellitus ( T1DM ) base disease diagnostic criterion duration diabetes ≥1 year hemoglobin A1c ≤10.0 % fast Cpeptide ≤0.3 nanomoles per liter ( nmol/L ) body mass index ≤29 kilograms per square meter ( kg/m² ) venous access sufficient allow blood sample cannulation clamp procedure currently enrol , complete , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device total insulin requirement &gt; 1.2 unit per kilogram per day ( U/kg/day ) history proliferative retinopathy know allergy insulin glargine , insulin lispro , heparin , related compound electrocardiogram ( ECG ) reading consider outside normal limit abnormal blood pressure abnormal clinical laboratory test history presence of/significant history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological neurological disorder capable significantly alter absorption , metabolism , elimination drug history deep leg vein thrombosis frequent appearance deep leg vein thrombosis firstdegree relative show evidence significant active neuropsychiatric disease regular use know drug abuse and/or show positive finding drug screen show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen woman positive pregnancy test woman lactate average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) 1 episode severe hypoglycemia within 6 month prior study undergo therapy malignancy basal cell squamous cell skin cancer blood transfusion severe blood loss within 3 month ; make blood donation within 30 day prior study entry ; know hemoglobinopathy , haemolytic anemia , sickle cell anemia receive systemic glucocorticoid therapy irregular sleep/wake cycle ( example , participant sleep day work night ) show history adverse reaction heparin , include heparininduced thrombocytopenia smoke 10 cigarette ( equivalent tobacco product ) per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>